 | |
| Clinical data | |
|---|---|
| Other names | CI-874, YM-08054 |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C14H17NO2 |
| Molar mass | 231.295 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Indeloxazine (INN; trade namesElen andNoin) is anantidepressant andcerebral activator[1][2] that was marketed inJapan andSouth Korea byYamanouchi Pharmaceutical Co., Ltd for the treatment ofpsychiatric symptoms associated withcerebrovascular diseases, namelydepression resulting fromstroke,emotional disturbance, andavolition.[3][4] It was marketed from 1988[4] to 1998, when it was removed from the market reportedly for lack of effectiveness.[5]
Indeloxazine acts as aserotonin releasing agent,norepinephrine reuptake inhibitor, andNMDA receptor antagonist.[6][7] It has been found to enhanceacetylcholine release in the ratforebrain through activation of the5-HT4 receptor via its action as a serotonin releasing agent.[8][9][10] The drug has been found to possessnootropic,[11][12]neuroprotective,[13][14][15][16]anticonvulsant,[17] andantidepressant-like effects inanimal models.[1][6]
